Direct answer
Some reviewed supplements can change risk markers: psyllium or plant sterols can lower LDL, omega-3 can lower triglycerides, and magnesium has a small average blood-pressure effect. Marker changes do not prove fewer heart attacks. CoQ10 heart-failure evidence is limited; folate findings depend on context. Check the exact product and medicines, and do not replace prescribed care.
Key takeaways
- A meta-analysis of 181 RCTs reported lipid-marker reductions with soluble fiber. Each 5 g/day increment was associated with LDL-C −5.57 mg/dL and total cholesterol −6.11 mg/dL. Overall pooled changes were larger; certainty was very low for LDL and low for total cholesterol, and the authors disclosed Isfahan University support. Source.
- Plant sterols/stanols can lower LDL-C, a risk marker. The 59-trial review found a 0.31 mmol/L reduction and disclosed food-company consulting; the 124-study analysis had two Unilever employees. These findings do not establish fewer heart attacks. 2008 review; 2014 dose analysis.
- Cochrane found little or no overall all-cause-mortality or combined cardiovascular-event benefit from long-chain omega-3. It also found triglyceride lowering and small, low-certainty coronary-event signals; these are different endpoints. Cochrane 2020.
- A 34-trial meta-analysis found small average blood-pressure reductions: about 2.00 mmHg systolic and 1.78 mmHg diastolic, at a median 368 mg/day over 3 months. The tested range does not establish one optimal dose. Zhang 2016.
- NCCIH reports no compelling detox benefit, and the historical 2002 homeopathy review found no convincing general efficacy. Neither is evidence for using these products to treat heart disease or delay medical care. NCCIH detox guidance; Homeopathy review.
The reviewed supplements have different uses and limits: soluble fiber/sterols can lower LDL, omega-3 lowers triglycerides, and magnesium has small average BP effects. CoQ10 heart-failure findings rely on limited adjunct trials; garlic and folate results do not establish universal cardiac protection (soluble fiber review, sterol review, omega-3 review, magnesium trials, CoQ10 review, garlic abstract, folate review). Detox and homeopathy evidence does not justify replacing prescribed care; chelation research used supervised IV regimens, not home supplement kits (NCCIH detox guidance, historical homeopathy review, NCCIH chelation guidance).
Table of contents
- Evidence summary
- Selected forms and uses
- Supplements with useful evidence
- Popular claims and their evidence limits
- Reported effects and precautions
- Selected interactions
- What works and what does not
- Sources and funding notes
Evidence summary
| Ingredient / claim | Evidence | Funding / conflict trace | Pure City verdict |
|---|---|---|---|
| Soluble fiber lowers lipid markers | Across 181 RCTs, overall LDL-C MD −8.28 mg/dL, total cholesterol −10.82, triglycerides −5.55 and apoB −44.99 mg/L. Per 5 g/day increment: LDL-C −5.57 and total cholesterol −6.11 mg/dL; these are different analyses Source | Author disclosures acknowledge Isfahan University of Medical Sciences support; the funding section says no study funding. Exact support terms are unexplained. Certainty: very low for LDL/TG/HDL, low for TC/apolipoproteins. | Favorable pooled marker results; certainty limited |
| Psyllium lowers LDL-C. | The 28-trial abstract reports LDL-C/non-HDL-C reductions of moderate certainty and apoB of high certainty; full original methods/disclosures were not recovered (psyllium meta-analysis). | Original abstract and primary records read; full review funding, author conflicts and all trial procurement terms remain unknown. | Works for LDL marker |
| Plant sterols/stanols lower LDL-C. | A 59-trial meta-analysis found plant sterol products decreased LDL-C by 0.31 mmol/L; a 124-study dose analysis found LDL-C reductions across 0.6–3.3 g/day intake ranges (plant sterol meta-analysis, plant sterol dose-response meta-analysis). | Jones disclosed food-company consulting in the 2008 review; Ras/Trautwein were Unilever employees in the 2014 analysis. The latter did not assess trial quality/heterogeneity/publication bias; all trial finances were not traced. | Works for LDL marker |
| Omega-3 EPA/DHA prevents cardiovascular events in general users. | Cochrane found little or no effect of increased long-chain omega-3 on all-cause mortality or cardiovascular events overall (Cochrane omega-3 review). | WHO/NIHR/UEA review support; authors declared none known. Included trial records identify Amarin-funded REDUCE-IT and donated products in ASCEND/VITAL. Nonprofit authorship does not clear all trial financing. | Mixed; works better for triglycerides |
| CoQ10 improves heart failure outcomes. | The 2021 review included 11 trials/1,573 people with chronic heart failure. Mortality benefit rested on one 420-person trial; hospital-admission benefit on two. Certainty ranged very low to moderate. NCCIH’s inconclusive summary dates to 2019 (Cochrane CoQ10 review, NCCIH CoQ10). | NIHR review infrastructure; authors declared no interests. Two included trials were partly manufacturer funded. Predominantly oral treatment, with one nasal-route study; no all-brand independence clearance. | Maybe, clinician-led adjunct |
| Magnesium lowers blood pressure. | 34 double-blind placebo-controlled trials found median 368 mg/day for 3 months reduced systolic BP by 2.00 mmHg and diastolic BP by 1.78 mmHg (magnesium BP meta-analysis). | IU Health–IU School of Medicine Strategic Research Initiative support; authors declared no conflicts. Complete financial chains of all 34 trials were not traced. | Small effect |
| Garlic improves cardiovascular risk factors. | A review published online 2025 (2026 issue) reported marker changes across 108 trials. Only its abstract/grant record was accessible; full methods/disclosures were not recovered. NCCIH’s 2021 digest notes small/low-quality BP studies (garlic RCT meta-analysis, NCCIH hypertension digest). | Kerman University of Medical Sciences grant 401000378 indexed; complete author disclosures and all underlying trial finance not recovered. NCCIH is guidance, not financial clearance. | Modest / mixed |
| Folate prevents heart disease. | NIH describes no coronary benefit from homocysteine lowering, with stroke findings dependent on folate/fortification context. The 2016 review included folic acid alone and combination B vitamins, not one universal regimen (NIH ODS folate, folic acid CVD meta-analysis). | The 2016 review was partly Metagenics funded; Frank Hu reported company research support and consultancy. NIH guidance does not clear every underlying trial’s finance. | Context-specific |
| Detoxes, cleanses, and homeopathic heart remedies treat heart disease. | NCCIH reports no compelling toxin-removal evidence. The 2002 review found no convincing general homeopathy efficacy, with search/review-method limits; it is not an exhaustive 2026 cardiac trial review (NCCIH detoxes and cleanses, homeopathy review of reviews). | Homeopathy author declared no financial interest and disclosed training in homeopathy; review cash funding not reported. Public NCCIH guidance is not a clearance of all underlying finances. | Do not rely |
Text version of infographic: Evidence ladder for heart supplements
| Item | Meaning |
|---|---|
| Strongest | Clinical-event evidence should be assessed for trial quality, endpoint relevance, precision and source conflicts; a review label alone does not prove a benefit. |
| Useful | LDL, triglyceride and BP changes are risk markers. Stroke is a clinical event; evidence should remain endpoint-specific. |
| Weak | Small studies, surrogate endpoints and product funding each require assessment; none alone supplies a universal reliability score. |
| Do not rely | Detoxes, homeopathy, and miracle-cure claims should not replace medical care. |
Selected forms and clinical roles
| Ingredient | Common forms | Evidence-supported use and limits | Evidence caveat |
|---|---|---|---|
| Omega-3 | Fish oil, krill oil, cod liver oil, algal EPA/DHA, purified EPA, mixed EPA+DHA, flax/chia ALA. | EPA/DHA for triglycerides; ALA is not equivalent because conversion to EPA/DHA is limited (NIH ODS omega-3). | Event-prevention claims depend on dose, form, population, background therapy, and trial funding. |
| CoQ10 | Ubiquinone, ubiquinol, oil-solubilized capsules, powders, gummies, enhanced-delivery formulas. | Heart-failure adjunct findings are limited and do not establish a best delivery form, brand or meal-timing rule (NCCIH CoQ10). | No universal comparative delivery-form winner is established here. |
| Magnesium | Citrate, glycinate/bisglycinate, oxide, chloride, lactate, malate, taurate, threonate, sulfate, hydroxide. | Correct inadequate intake when indicated. Some salts absorb better than oxide, but the cited guidance does not establish glycinate as the best-tolerated repletion form (NIH ODS magnesium). | Heart-specific BP effect is modest; avoid unsupervised use in kidney disease. |
| Soluble fiber | Psyllium husk, beta-glucan from oats/barley, glucomannan, guar gum, pectin, inulin/resistant dextrin blends. | The review found lipid-marker reductions with isolated soluble fibers, but LDL certainty was very low. It does not establish every named fiber or blend as equally effective (soluble fiber meta-analysis). | Psyllium requires sufficient liquid and medicine-specific spacing; rules are product-specific (MedlinePlus psyllium). |
| Plant sterols/stanols | Free sterols, sterol esters, stanols, stanol esters, fortified foods, capsules, powders. | LDL-C lowering through reduced cholesterol absorption; sterols and stanols both work (plant sterol dose-response meta-analysis). | The review searching through January 2023 identified no hard-event RCT; sitosterolemia is a contraindication (plant sterol review). |
| Garlic | Garlic powder, aged garlic extract, garlic oil, raw garlic, deodorized preparations. | Risk-marker evidence varies across preparations. Supplements can increase bleeding risk, particularly around procedures (NCCIH garlic). | Do not assume culinary garlic effects equal concentrated supplement effects. |
| Folate | Folic acid, folinic acid, L-5-MTHF, food folate. | The cited clinical evidence includes folic acid alone and combination B vitamins; B12 status and medicines matter (NIH ODS folate; 2016 review). | Stroke evidence is context-specific; coronary prevention is not convincing. |
Supplements with useful evidence
Soluble fiber: lipid-marker findings and their limits
The 181-trial review found lipid-marker changes, but LDL certainty was very low because of heterogeneity and bias. The 28-trial psyllium abstract reports moderate-certainty LDL/non-HDL effects. A marker result is not evidence of fewer heart attacks, and the full psyllium paper/disclosures were not recovered (soluble fiber meta-analysis, psyllium meta-analysis).
For psyllium, follow the exact product directions, take it with adequate liquid, and ask about medicine-specific spacing. Do not substitute a fiber product for prescribed lipid treatment. The cited evidence does not establish one optimal introductory schedule for every soluble fiber. MedlinePlus directions; AAFP interaction review.
Plant sterols and stanols: LDL lowering without event proof
Plant sterols and stanols can lower LDL-C, with effects depending on dose and food vehicle. The 2008 meta-analysis excluded capsules/tablets; the 2023 narrative review, searching through January 2023, found no hard-outcome trial proving fewer heart attacks or strokes. Keep LDL reduction separate from event prevention (plant sterol meta-analysis, plant sterol review).
Omega-3: strong for triglycerides, mixed for prevention
Omega-3 is a classic example of form and dose mattering. NIH ODS notes that omega-3 trial findings vary by form, population, background diet, statin use, and dose; Cochrane found little or no overall cardiovascular-event benefit for increased omega-3 intake in long-term RCTs (NIH ODS omega-3, Cochrane omega-3 review).CoQ10: possible adjunct, not core heart therapy
CoQ10 heart-failure findings are adjunct evidence. In the 2021 review, a mortality signal rested on one trial and admission benefit on two; certainty varied by outcome. NCCIH’s 2019 summary calls the findings inconclusive and overall statin-muscle-pain evidence unsupportive. These findings do not replace prescribed care or transfer to every formulation (Cochrane CoQ10 review, NCCIH CoQ10).
Magnesium: useful if low, modest for blood pressure
Magnesium supplementation modestly lowered BP in double-blind RCTs, but the average effect was small. NIH ODS lists diarrhea, nausea, cramping, and medication interactions, and warns that very high magnesium from supplements or medicines can cause toxicity, especially when kidney function is impaired (magnesium BP meta-analysis, NIH ODS magnesium).Garlic and folate: limited, context-specific
Garlic’s cited review reports risk-marker changes, with full methods/disclosures inaccessible; concentrated products have bleeding cautions. Folate lowers homocysteine, but that does not establish coronary-event prevention. Stroke findings vary with folate status, fortification and regimen; B12 status and medicines need review (garlic RCT meta-analysis, NCCIH garlic, NIH ODS folate).
Text version of infographic: Ingredient-to-target matching
| Item | Meaning |
|---|---|
| LDL-C | Soluble fiber and sterols can lower LDL-C; certainty, formulation and outcome evidence differ. |
| Triglycerides | EPA/DHA can lower triglycerides; this does not establish universal event prevention. |
| Blood pressure | Magnesium has small average BP effects; garlic evidence is mixed. |
| Heart failure adjunct | CoQ10 belongs in clinician-led add-on discussions, not self-treatment. |
| Stroke context | Folate is context-specific and must account for B12 status and interacting medicines. |
Popular claims and their evidence limits
| Popular claim | Verdict | Why Pure City downgrades it | Better alternative |
|---|---|---|---|
| “Heart detox” or “artery cleanse” kits | DOESN’T | NCCIH says detox and cleanse studies are low quality and there is no compelling evidence that detox diets eliminate toxins; some products have contained hidden ingredients or false disease-treatment claims (NCCIH detoxes and cleanses). | Measure BP, LDL-C, glucose/A1c, and symptoms; use proven prevention. |
| Homeopathic heart drops | DOESN’T | The 2002 review found no convincing general homeopathy efficacy, while noting review/search limits. The author disclosed homeopathy training and no financial interest (homeopathy review of reviews). | Use evidence-based care; seek urgent help for chest symptoms. |
| “Natural blood thinner” blends | Unsafe claim | The review reports different evidence for different ingredients: garlic surgical bleeding, hawthorn perioperative association and ginkgo with warfarin. These do not validate unspecified blends or replace prescribed anticoagulation (dietary supplements and bleeding review). | Use prescribed anticoagulants/antiplatelets exactly as directed. |
| Red-flag cholesterol blends with undisclosed actives | INSUFFICIENT / avoid if undisclosed | An undisclosed blend cannot be clinically matched to an ingredient trial without its actual components and doses. | Require disclosed ingredients/doses and pharmacist review; transparent labeling does not itself prove efficacy or safety. |
| Chelation-style oral supplement kits | DOESN’T as self-care | NCCIH warns against OTC/home chelation products; research involved IV treatment, not oral kits. TACT2’s 2025 vitamin paper found no significant event benefit from its high-dose 28-component regimen, alone or with EDTA (NCCIH chelation guidance; TACT2 vitamin trial). | Use clinician-directed secondary prevention and rehab. |
| “MTHFR heart cure” methylfolate marketing | Overstated | NIH ODS says folic acid/B vitamins lower homocysteine but do not clearly reduce overall CVD risk, although stroke signals exist; MTHFR claims should not replace measured folate/B12 assessment (NIH ODS folate). | Check folate/B12 status and medicines with a clinician. |
Text version of infographic: Red flags in heart supplement marketing
| Item | Meaning |
|---|---|
| Cleans arteries | The cited NCCIH guidance does not establish detox products as a treatment for atherosclerotic disease. |
| Replaces medicines | Supplements should not replace statins, BP medicines, anticoagulants, antiplatelets, or heart-failure medicines without clinician direction. |
| No interactions | Check each actual ingredient, product and medicine; a universal no-interaction promise cannot be inferred from limited studies. |
| Clinically proven | The claim must specify ingredient form, dose, population, trial design, and outcome. |
Reported effects and safety precautions
| Ingredient | Reported effects | Important risks and uncertainties | At-risk populations | Sources and limits |
|---|---|---|---|---|
| Omega-3 EPA/DHA | Fishy burps, unpleasant taste, nausea, loose stools. | Some 4 g/day long-term trials found increased AF. Most studies summarized by NIH did not show clinically important bleeding; discuss seafood allergy and the exact product. | Anticoagulant/antiplatelet users, atrial fibrillation history, surgery planning, seafood allergy. | NIH ODS omega-3 |
| CoQ10 | Digestive upset, nausea, diarrhea, appetite loss, insomnia. | Possible warfarin interaction and oncology concerns, including preclinical radiation evidence; not every treatment interaction is clinically established. | Warfarin or insulin use, cancer treatment and limited pregnancy/lactation data warrant professional review. | NCCIH CoQ10; MSKCC CoQ10 |
| Magnesium | Diarrhea, nausea, abdominal cramping. | Hypermagnesemia with excessive supplemental/medicinal magnesium, especially with impaired renal clearance. | Kidney disease, older adults with reduced kidney function, users of magnesium laxatives/antacids. | NIH ODS magnesium |
| Soluble fiber / psyllium | Gas, bloating, fullness and stool changes. | Swelling creates a choking/obstruction concern if swallowed without sufficient liquid; some oral-drug absorption may change. | Difficulty swallowing or intestinal blockage; medicines need a spacing plan. | ASHP/MedlinePlus precautions; AAFP interaction review Source 1 Source 2 |
| Plant sterols/stanols | Carotenoid reductions can occur; digestive-effect frequencies are not established here. | Avoid in sitosterolemia; long-term clinical-outcome safety remains uncertain. | Pediatric familial-hypercholesterolemia treatment is specialist care; pregnancy/lactation decisions need individualized advice. | plant sterol review |
| Garlic supplements | Oral odor, abdominal pain, gas, nausea or allergy may occur. | Bleeding risk; allergic reactions; topical raw garlic burns. | Anticoagulant/aspirin use, planned surgery and above-food pregnancy/lactation use warrant review. | NCCIH garlic |
| Folate / folic acid | No universal frequency is established here; dose and formulation matter. | High folic acid can correct B12-related anemia while neurological injury continues. Methotrexate and seizure-medicine decisions depend on the treatment regimen. | B12 deficiency risk, epilepsy medicines, methotrexate, cancer therapy. | NIH ODS folate |
Selected interactions and precautions
| Ingredient | Interacts with | Mechanism | Severity | Action |
|---|---|---|---|---|
| Omega-3 | Anticoagulants/antiplatelets and planned procedures | High doses can affect clotting, but most reviewed studies did not show clinically important bleeding; a universal clinical interaction is not established. | Use with caution | Disclose use and avoid unsupervised high doses (NIH ODS omega-3). |
| Omega-3 | Atrial fibrillation history | Some 4 g/day long-term trials found increased AF; ask the treating clinician about the exact product and dose (NIH ODS omega-3). | Monitor / clinician-led | Use clinician-supervised dosing only. |
| CoQ10 | Warfarin | Case reports and reference guidance suggest an interaction; direction and magnitude are not reliably predictable. | Monitor INR | Do not start/stop without INR plan (NCCIH CoQ10). |
| CoQ10 | Insulin | NCCIH reports a possible insulin interaction; class-wide BP/glucose interactions are not established here. | Monitor | Discuss use with the insulin prescriber; do not change medicines yourself (NCCIH CoQ10). |
| CoQ10 | Chemotherapy/radiation | Concerns include animal radiation findings and clinical associations, not proof every regimen becomes less effective. | Avoid unless approved | Oncology team decides (MSKCC CoQ10). |
| Magnesium | Bisphosphonates; tetracycline and quinolone antibiotics | Mineral chelation reduces drug absorption. | Separate doses | Separate per medicine label/pharmacist guidance (NIH ODS magnesium). |
| Magnesium | Diuretics, PPIs, kidney disease | Loop/thiazide diuretics can increase magnesium loss; potassium-sparing drugs reduce excretion. Long-term PPIs can cause low magnesium; kidney impairment increases toxicity risk. | Monitor / avoid unsupervised | Check labs when indicated (NIH ODS magnesium). |
| Soluble fiber / psyllium | Carbamazepine, lithium and some other oral medicines | Reduced absorption reported for carbamazepine and in a lithium case report; advice varies by drug. | Separate doses | MedlinePlus advises a 3-hour gap for digoxin, aspirin/salicylates and nitrofurantoin. Ask a pharmacist about each medicine. Source 1 Source 2 |
| Plant sterols/stanols | Sitosterolemia; bile acid sequestrants; fat-soluble nutrients | Sitosterolemia increases sterol burden; carotenoids can decline. The review does not recommend combining sterols with bile-acid sequestrants because evidence/absorption are limited. | Avoid in sitosterolemia; monitor otherwise | Avoid in sitosterolemia and review the exact product/medicine combination with the lipid prescriber (plant sterol review). |
| Garlic | Anticoagulants/aspirin and planned surgery | Platelet effects and surgical bleeding associations support caution; a causal risk for every medicine combination is not quantified. | Use with caution | Stop before procedures if advised; disclose use (NCCIH garlic, dietary supplements and bleeding review). |
| Garlic | Saquinavir | NCCIH’s 2021 hypertension digest reports interference with saquinavir effectiveness. | Avoid/monitor | Ask the prescribing pharmacist about the exact combination (NCCIH general garlic safety; NCCIH saquinavir caution). |
| Folate | Methotrexate, named seizure medicines, sulfasalazine and B12 deficiency | Methotrexate oncology and low-dose autoimmune regimens differ; prescribed folate may help with the latter. Seizure medicines and sulfasalazine can alter folate; high intake can conceal B12-related anemia. | Clinician-led | Follow the prescriber’s regimen; do not start, stop or withhold prescribed folate based on a generic list (NIH ODS folate). |
Text version of infographic: Safety triage before buying
| Item | Meaning |
|---|---|
| Target | Choose supplements only for a measurable target. |
| Dose/form | Evidence is not transferable across all forms and doses. |
| Medicines | Check interactions with anticoagulants, antiplatelets, BP drugs, diabetes medicines, thyroid medicines, antiepileptics, and cancer drugs. |
| Stop rules | Seek care for concerning symptoms and follow a clinician-agreed plan; do not stop prescribed heart medicines based on this supplement checklist. |
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|---|---|---|
| Soluble fiber lowers LDL-C. | WORKS | Soluble-fiber LDL certainty very low; psyllium abstract LDL certainty moderate. | Separate from some medicines and take with fluid. |
| Plant sterols/stanols lower LDL-C. | WORKS | 59-trial and 124-study meta-analyses. | No event benefit established by the review through January 2023; avoid sitosterolemia. |
| Omega-3 lowers triglycerides. | WORKS | NIH ODS and clinical trial evidence. | Event prevention is mixed; high-dose use requires clinician review. |
| Omega-3 prevents heart attacks in all adults. | DOESN’T | Cochrane found little/no overall CVD event benefit. | Do not extrapolate from prescription high-dose trials to low-dose OTC capsules. |
| CoQ10 helps selected heart-failure patients. | MIXED / POSSIBLE | 2021 Cochrane mortality signal from one trial; 2019 NCCIH summary inconclusive. | Use only as adjunct; check warfarin and oncology interactions. |
| Magnesium meaningfully treats hypertension alone. | DOESN’T | Average BP reduction about 2/1.8 mmHg. | Correcting inadequate intake differs from treating hypertension; renal impairment requires supervision. |
| Garlic replaces BP or cholesterol medicines. | DOESN’T | Risk-marker evidence mixed and modest. | Bleeding interactions matter. |
| Folate prevents heart attacks. | INSUFFICIENT | The 2016 meta-analysis found no coronary benefit; stroke findings were context-dependent. | B12 and interacting medicines matter. |
| Detoxes/cleanses clean arteries. | DOESN’T | NCCIH finds no compelling detox evidence. | May contain hidden ingredients or delay care. |
| Homeopathy treats heart disease. | DOESN’T | The 2002 review found no convincing general clinical efficacy; not a heart-specific 2026 search. | Dangerous if used for chest pain or diagnosed disease. |
Text version of infographic: Final verdict matrix
| Item | Meaning |
|---|---|
| Selected LDL-marker options | Soluble fiber and sterols can lower LDL-C; certainty and formulation differ, and this does not rank them against prescribed treatments. |
| Use selectively | Omega-3, magnesium, and CoQ10 require the right indication and safety review. |
| Use cautiously | Garlic and folate can be useful but interactions and context matter. |
| Avoid as treatment | Detoxes, cleanses, homeopathy, miracle blends, and oral chelation kits should not be used as heart disease treatment. |
Frequently asked questions
What is the best supplement for heart disease?
There is no universal best heart supplement in the evidence reviewed here. Psyllium/sterols can lower LDL-C, omega-3 can lower triglycerides, and magnesium has small average BP effects. Marker improvements do not guarantee fewer heart attacks; deficiency correction is a separate nutritional need (soluble fiber meta-analysis, NIH ODS omega-3). Sterol dose evidence; NIH magnesium guidance.
Does fish oil prevent heart attacks?
Not as a blanket claim. Cochrane found little or no overall effect of increased long-chain omega-3 on cardiovascular events, while some high-dose purified EPA evidence differs by population and product; that makes fish oil a targeted triglyceride or clinician-led adjunct discussion, not universal heart insurance (Cochrane omega-3 review, NIH ODS omega-3).
Can CoQ10 be taken with statins?
NCCIH’s overall summary does not support CoQ10 for statin-related muscle pain. It reports possible warfarin and insulin interactions, not established effects with every BP or diabetes medicine. Review the exact regimen with the clinician or pharmacist (NCCIH CoQ10).
Are plant sterols safer than statins?
The cited evidence cannot establish a universal comparative safety ranking. Sterols lower LDL-C, but the review through January 2023 identified no hard-event RCT; statins have large event trials. Sitosterolemia is a sterol contraindication, and carotenoids can fall (plant sterol review, CTT meta-analysis).
Is garlic safe for the heart?
Food-level garlic is different from concentrated garlic supplements. NCCIH lists breath/body odor, abdominal pain, flatulence, nausea, allergy, topical burns from raw garlic, and increased bleeding risk with anticoagulants or aspirin-like medicines (NCCIH garlic).
Should folate be used for MTHFR and heart disease?
Folate decisions should be based on measured status, diet, pregnancy-related needs when relevant, B12 status, and medicines, not genetic marketing alone. NIH ODS says folic acid/B vitamins lower homocysteine but do not clearly lower overall cardiovascular disease risk, although stroke reduction signals are stronger (NIH ODS folate).
Are detoxes or cleanses useful for heart disease?
No credible evidence supports detoxes or cleanses as heart-disease treatment. NCCIH reports low-quality detox studies and no compelling evidence for toxin elimination, and some products have been targeted for hidden ingredients or false serious-disease claims (NCCIH detoxes and cleanses).
Sources and funding notes
Follow the money
Research funding at a glance
Funding & backers→Source & study→Claim & limits
13 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
No single explicit tier could be mapped. This graphic does not assign a new tier or infer independence.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | URL | Funding / conflict note |
|---|---|---|
| Soluble fiber meta-analysis | PMC 10201678 Source | Isfahan University of Medical Sciences support acknowledged in author disclosures; no study funding stated separately. Exact support terms unexplained; underlying trial finances not fully cleared. |
| Psyllium meta-analysis | PubMed 30239559 | Original abstract/GRADE read; complete original funding/conflicts and trial product terms not recovered. |
| Plant sterol meta-analysis | PMC 2596710; 2014 dose analysis | Jones food-company consulting in 2008; 2014 dose analysis had Unilever-employed Ras/Trautwein. All underlying trial finance not traced. |
| Omega-3 Cochrane review | Cochrane CD 003177 | WHO/NIHR/UEA review support, declarations none known. Amarin-funded REDUCE-IT and donated products in ASCEND/VITAL; all trial finances not fully traced. |
| CoQ10 Cochrane review | PMC 8092430 | NIHR review infrastructure; author interests none declared. Two partly manufacturer-funded trials, one nasal-route study and single-trial mortality dependence. |
| Magnesium BP meta-analysis | PubMed 27402922 | IU Health–IU School of Medicine Strategic Research Initiative support; no author conflicts declared. Included-trial finances not fully traced. |
| Garlic safety | NCCIH garlic | Public NIH guidance; page-specific contributor financing/declarations and every underlying-study financial chain are not completely supplied. |
| Folate safety | NIH ODS folate | Public NIH guidance; page-specific contributor financing/declarations and every underlying-study financial chain are not completely supplied. |
| Detoxes and cleanses | NCCIH detoxes and cleanses | Public NIH guidance; page-specific contributor financing/declarations and every underlying-study financial chain are not completely supplied. |
| Homeopathy review of reviews | PMC 1874503 | Historical 2002 review; author trained homeopath, no financial interest declared. Review cash financing and all cited-review finances not reported. |
| Folic acid 2016 meta-analysis | PubMed 27528407 | Partly Metagenics funded; Frank Hu company support/consultancy. Mixed regimes/populations, no coronary benefit. |
| Garlic risk-marker review | PubMed 40580481 | Kerman grant 401000378 indexed. Original abstract read; full methods and declarations not recovered. |
| TACT2 vitamin trial 2025 | PMC 11877407 | NIH support, with author pharmaceutical grant/consulting ties disclosed. Oral caplet procurement terms not stated in the main paper; no significant event benefit in diabetes/prior MI. |
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.